Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on July 01, 2019, 11:57:01 am
-
People who used an experimental hepatitis B virus (HBV) core protein inhibitor along with nucleoside/nucleotide analogues saw greater reductions in HBV viral load and residual HBV genetic material, which could lead to a functional cure with longer follow-up, according to a study presented at the 2019 International Liver Congress in Vienna.
The novel treatment was well tolerated, and the rapid, deep declines in HBV DNA and RNA could promote the loss of cccDNA (covalently closed circular DNA), an intermediate form that persists in the nucleus of liver cells and presents a barrier to a cure, said Jay Lalezari, MD, of Quest Clinical Research in San Francisco.
For more...
https://www.hepmag.com/article/core-protein-inhibitor-boosts-antiviral-activity-hepatitis-b